APA (7th ed.) Citation

MG, D., AC, T., L, W., B, N., P, d. R., J, v. d. L., . . . UA, v. d. H. (2026). Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer. International journal of radiation oncology, biology, physics, 125(1), 257. https://doi.org/10.1016/j.ijrobp.2025.11.028

Chicago Style (17th ed.) Citation

MG, Dassen, et al. "Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer." International Journal of Radiation Oncology, Biology, Physics 125, no. 1 (2026): 257. https://doi.org/10.1016/j.ijrobp.2025.11.028.

MLA (9th ed.) Citation

MG, Dassen, et al. "Primary Endpoint Analysis of the Phase 2 DESTINATION-MRL Trial for Patients With Intermediate-Risk Prostate Cancer." International Journal of Radiation Oncology, Biology, Physics, vol. 125, no. 1, 2026, p. 257, https://doi.org/10.1016/j.ijrobp.2025.11.028.